Corcept Therapeutics to Announce Audited Financial Results, Provide Corporate Update and Host Conference Call
February 13, 2020 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its audited 2019 fourth quarter and full-year financial results...
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2019 Preliminary Selected Financial Results; Provides 2020 Revenue Guidance
January 30, 2020 16:05 ET
|
Corcept Therapeutics Incorporated
2019 revenue of $306.5 million, an increase of 22 percent from 2018Fourth quarter revenue of $87.9 million, an increase of 32 percent from fourth quarter 2018Cash and investments at December 31, 2019,...
Corcept Therapeutics Announces Third quarter 2019 Financial Results and provides corporate update
November 07, 2019 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 31, 2019 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update...
Corcept Therapeutics Appoints Kimberly Park to Board of Directors
September 18, 2019 08:30 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome
August 28, 2019 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that the United States Patent and Trademark Office has issued a Notice of...
Corcept Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update
August 01, 2019 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 25, 2019 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update...
Corcept Therapeutics to Present Data from Phase 1/2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Solid Tumors at the American Society of Clinical Oncology Annual Meeting
May 28, 2019 08:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe...
Corcept Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 09, 2019 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...